Federal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
FILE - A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018. Federal health advisers voted against an experimental treatment for Lou Gehrigs disease at a Wednesday, Sept. 27, 2023, meeting prompted by years of patient efforts seeking access to the unproven therapy.
released earlier this week, in which staff scientists described Brainstorm’s application as “scientifically incomplete” and “grossly deficient.”
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA to Review Experimental ALS Treatment This WeekThe Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig's disease, the culmination of a yearslong lobbying effort by patients with the fatal neurodegenerative disease. Those advocates still face one giant hurdle: FDA...
続きを読む »
| FDA advisers weigh divisive ALS drug todayThere's a heated debate over the investigational treatment called NurOwn.
続きを読む »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
続きを読む »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
続きを読む »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
続きを読む »